On Aug. 5, 2022, the U.S. Food and Drug Administration approved Enhertu to treat unresectable or metastatic HER2-low breast cancer.
The U.S. Food and Drug Administration (FDA) has approved Keytruda plus chemotherapy before surgery, followed by Keytruda alone after surgery to treat early-stage triple-negative breast cancer with a high risk of recurrence.
The immunotherapy medicine Keytruda plus chemotherapy before surgery and Keytruda alone after surgery improved event-free survival better than chemotherapy alone in women diagnosed with early-stage triple-negative breast cancer.
After taking 5 years of hormonal therapy following surgery, postmenopausal women diagnosed with early-stage hormone-receptor-positive breast cancer got the same benefits from taking 2 more years of Arimidex as they did from taking 5 more years, with fewer side effects.
Survival rates were the same in postmenopausal women diagnosed with early-stage hormone-receptor-positive breast cancer whether they took a short treatment break during extended adjuvant hormonal therapy with Femara or took Femara continuously for 5 years after previously taking hormonal therapy for an initial 5 years.
On Aug. 27, 2021, Genentech announced it is voluntarily withdrawing the breast cancer indication from the immunotherapy medicine Tecentriq in the United States.
Six months after receiving their second dose of the Pfizer COVID-19 vaccine, people diagnosed with solid tumor cancers had about the same antibody levels as people who hadn’t been diagnosed with cancer.
A combination of surgery and systemic therapy can improve survival more than systemic therapy alone for women diagnosed with stage IV breast cancer with known hormone receptor and HER2 status.
Adding carboplatin (brand name: Paraplatin) to the standard neoadjuvant chemotherapy regimen for early-stage triple-negative breast cancer improved event-free survival.
People diagnosed with metastatic cancer that has spread to the bones can safely participate in supervised exercise programs, according to a review of 17 studies.
Enhertu more than doubled the 12-month progression-free survival rate than Kadcyla in people diagnosed with metastatic HER2-positive breast cancer that had been previously treated.
After taking tamoxifen for 2 to 3 years following surgery, postmenopausal women diagnosed with early-stage hormone-receptor-positive breast cancer had a better survival rate from taking 5 years of Femara rather than 2 to 3 years of Femara.
Telling children that their mothers have a genetic risk of developing breast and ovarian cancer doesn’t affect their long-term quality of life.
Metastatic breast cancer responded better to a combination of the chemotherapy medicine paclitaxel in pill form and encequidar (a medicine that allows oral paclitaxel to be absorbed into the bloodstream) than to intravenous paclitaxel.
Women with a genetic mutation linked to a higher cancer risk who are diagnosed with breast cancer or ovarian cancer and receive chemotherapy treatment have the same or better survival rates as women who don’t have a genetic mutation linked to higher risk.
Women diagnosed with breast cancer who exercised before, during, and after chemotherapy were less likely to have chemo brain.
General oncologists have received new specific, practical recommendations on how to offer individualized palliative care to people diagnosed with metastatic breast cancer.
On Dec. 20, 2019, the U.S. Food and Drug Administration approved Enhertu (chemical name: fam-trastuzumab deruxtecan-nxki) to treat people diagnosed with unresectable HER2-positive breast cancer or metastatic HER2-positive breast cancer that has been treated with two or more anti-HER2 therapies.
Compared with doctors’ choice of chemotherapy, Enhertu (chemical name: fam-trastuzumab-deruxtecan-nxki) improved both progression-free survival and overall survival in people diagnosed with previously treated metastatic HER2-low breast cancer.
A new study by the Centers for Disease Control and Prevention echoes the results of other studies: Breast cancer screening rates dropped dramatically at the beginning of the COVID-19 pandemic, especially among women of certain racial and ethnic groups.
When more Black women diagnosed with early-stage, triple-negative breast cancer joined a study on Imfinzi, the results showed the immunotherapy was as effective in Black women as it was in women of other races and ethnicities.
Exercise helped reduce the risk of heart problems in women receiving treatment for breast cancer.
Fezolinetant, an experimental medicine that doesn’t contain hormones, has successfully treated hot flashes.
In women with extremely dense breasts and a high risk of breast cancer, screening with 3D mammograms — rather than 2D digital mammograms — was linked to a lower risk of advanced-stage disease.